Results 101 to 110 of about 47,525 (299)

In Vitro Assessment of Drug‐Induced Liver Injury Using Three‐Dimensional Cultured HepaSH Cells Derived From Chimeric Mouse Model With Humanized Liver

Journal of Applied Toxicology, EarlyView.
ABSTRACT Drug‐induced liver injury (DILI) is a serious adverse event and a common cause of postmarketing drug withdrawal. Despite nonclinical assessments of DILI risk, which are predominantly conducted in experimental animals, DILI remains a frequent adverse event, highlighting the need to improve nonclinical assessments.
Xingming Liu, Yuichiro Higuchi, Yuta Sakamoto, Shota Yanagida, Shotaro Uehara, Hiroshi Suemizu, Yasunari Kanda, Hiroyuki Kawagishi   +7 more
wiley   +1 more source

Development of Customizable Implementation Guides to Support Clinical Adoption of Pharmacogenomics: Experiences of the Implementing GeNomics In pracTicE (IGNITE) Network

Pharmacogenomics and Personalized Medicine, 2020
Benjamin Q Duong,1 Meghan J Arwood,2 J Kevin Hicks,3 Amber L Beitelshees,4 Francesco Franchi,5 John T Houder,2 Nita A Limdi,6 Kelsey J Cook,7,8 Aniwaa Owusu Obeng,9 Natasha Petry,10 Sony Tuteja,11 Amanda R Elsey,2 Larisa H Cavallari,2 Kristin Wiisanen2 ...
Duong BQ, Arwood MJ, Hicks JK, Beitelshees AL, Franchi F, Houder JT, Limdi NA, Cook KJ, Owusu Obeng A, Petry N, Tuteja S, Elsey AR, Cavallari LH, Wiisanen K   +13 more
doaj  

Allelic variants of the cyp2d6: *4, *6 and *10 in a sample of resident from the Aragua state, Venezuela

Revista Peruana de Medicina Experimental y Salud Pública, 2015
The aim of this study was to determine the CYP2D6: * 4, * 6 and * 10 gene variants frequency and to predict the metabolizer phenotype in a sample of 145 unrelated apparently healthy individuals residing in the state of Aragua, Venezuela.
Carlos Flores-Angulo, Cecilia Villegas, Yuselin Mora, José Antonio Martínez, Teresa Oropeza, Nancy Moreno   +5 more
doaj   +1 more source

Metabolism and Metabolic Inhibition of Xanthotoxol in Human Liver Microsomes [PDF]

, 2016
Cytochrome p450 (CYP450) enzymes are predominantly involved in Phase I metabolism of xenobiotics. In this study, the CYP450 isoforms involved in xanthotoxol metabolism were identified using recombinant CYP450s.
Cai, Jiqun, Guo, Feng, Ma, Zhongnv, Shan, Lina, Shi, Xianbao, Zhang, Gang   +5 more
core   +5 more sources

Dextromethorphan versus Dextrorphan: A Quantitative Comparison of Antitussive Potency following Separate Administration of Metabolite

The Journal of Clinical Pharmacology, EarlyView.
Abstract To assess the antitussive effects of dextrorphan (DOR) relative to its parent compound, dextromethorphan (DEX) a double‐blind, randomized, placebo‐controlled crossover study was conducted in 23 healthy volunteers using citric acid cough challenge test after administering placebo, DEX, or DOR.
Saeed Rezaee, Caroline E. Wright, Alyn H. Morice, Amin Rostami‐Hodjegan   +3 more
wiley   +1 more source

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia

Pharmacogenomics and Personalized Medicine, 2020
Monpat Chamnanphon,1 Sorawit Wainipitapong,2 Teeravut Wiwattarangkul,3 Phenphichcha Chuchuen,2 Kunathip Nissaipan,1,4 Weeraya Phaisal,1,4 Sookjaroen Tangwongchai,2 Chonlaphat Sukasem,5 Supeecha Wittayalertpanya,1,4 Andrea Gaedigk,6 Daruj Aniwattanapong,2
Chamnanphon M, Wainipitapong S, Wiwattarangkul T, Chuchuen P, Nissaipan K, Phaisal W, Tangwongchai S, Sukasem C, Wittayalertpanya S, Gaedigk A, Aniwattanapong D, Chariyavilaskul P   +11 more
doaj  

Characterization of hepatic enzyme activity in older adults with dementia: potential impact on personalizing pharmacotherapy [PDF]

, 2015
OBJECTIVE: To determine the frequency of pharmacogenomic variants and concurrent medications that may alter the efficacy and tolerability of acetylcholinesterase inhibitors (AChEIs).
Boustani, Malaz A., Campbell, Noll L., Gao, Sujuan, Khan, Babar A., Li, Lang, Perkins, Anthony J., Skaar, Todd C.   +6 more
core   +2 more sources

Clinical Evaluation of Drug–Drug Interactions Between Bictegravir and Strong Inhibitors/Inducers of the CYP3A4, UGT1A1, or P‐gp Pathways

The Journal of Clinical Pharmacology, EarlyView.
Abstract In addition to antiretroviral therapy (ART), people with HIV often take medications to treat comorbidities. It is therefore important to assess these medications for potential drug‐drug interactions, which may affect the safety and efficacy of ART. Three phase I studies were conducted in adult participants without HIV. The pharmacokinetics (PK)
Priyanka Arora, Hui Liu, John Ling, Jason T. Hindman, Dhananjay D. Marathe   +4 more
wiley   +1 more source

Evaluation of the Effect of CYP2D6 Genotypes on Tramadol and O-Desmethyltramadol Pharmacokinetic Profiles in a Korean Population Using Physiologically-Based Pharmacokinetic Modeling

Pharmaceutics, 2019
Tramadol is a μ-opioid receptor agonist and a monoamine reuptake inhibitor. O-desmethyltramadol (M1), the major active metabolite of tramadol, is produced by CYP2D6.
Hyeon-Cheol Jeong, Soo Hyeon Bae, Jung-Woo Bae, Sooyeun Lee, Anhye Kim, Yoojeong Jang, Kwang-Hee Shin   +6 more
doaj   +1 more source

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group

Clinical and Translational Science, 2020
Translating CYP2D6 genotype to metabolizer phenotype is not standardized across clinical laboratories offering pharmacogenetic (PGx) testing and PGx clinical practice guidelines, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and ...
Kelly E. Caudle, Katrin Sangkuhl, Michelle Whirl‐Carrillo, Jesse J. Swen, Cyrine E. Haidar, Teri E. Klein, Roseann S. Gammal, Mary V. Relling, Stuart A. Scott, Daniel L. Hertz, Henk‐Jan Guchelaar, Andrea Gaedigk   +11 more
doaj   +1 more source